Journal
JOURNAL OF IMMUNOLOGY
Volume 182, Issue 11, Pages 6815-6823Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0802008
Keywords
-
Categories
Funding
- Baylor Health Care Systems Foundation
- National Institutes of Health [U19 AIO57234, CA78846]
- Caruth Chair for Transplantation Immunology Research
- Michael A. Ramsay Chair for Cancer Immunology Research
Ask authors/readers for more resources
Plasmacytoid dendritic cells (pDCs) are key regulators of antiviral immunity. They rapidly secrete IFN-alpha and cross-present viral Ags, thereby launching adaptive immunity. In this study, we show that activated human pDCs inhibit replication of cancer cells and kill them in a contact-dependent fashion. Expression of CD2 distinguishes two pDC subsets with distinct phenotype and function. Both subsets secrete IFN-alpha and express granzyme B and TRAIL CD2(high) pDCs uniquely express lysozyme and can be found in tonsils and in tumors. Both subsets launch recall T cell responses. However, CD2(high) pDCs secrete higher levels of IL12p40, express higher levels of costimulatory molecule CD80, and are more efficient in triggering proliferation of naive allogeneic T cells. Thus, human blood pDCs are composed of subsets with specific phenotype and functions. The Journal of Immunology, 2009, 182: 6815-6823.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available